- Risk of Bleeding

- Rash

- Anemia

- Abnormal liver function tests

- Interstitial lung disease (ILD)

Early stoppage of edoxaban and the lack of sufficient alternative anticoagulation can increase the risk of ischemic events. Transitioning to another agent should be considered in the absence of pathological bleeding.